Evidence map›Paper›PMID 33995006›Full record

ArticleFrontiers in pharmacology2021

Translational Studies on Anti-Atrial Fibrillatory Action of Oseltamivir by its

Ryuichi Kambayashi, Hiroko Izumi-Nakaseko, Ai Goto, Kazuya Tsurudome, Hironori Ohshiro, Taku Izumi, Mihoko Hagiwara-Nagasawa, Koki Chiba, Ryota Nishiyama, Satomi Oyama and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Ryuichi KambayashiDepartment of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.
Hiroko Izumi-NakasekoDepartment of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.
Ai GotoDepartment of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.
Kazuya TsurudomeSophion Bioscience K.K., Saitama, Japan.
Hironori OhshiroSophion Bioscience K.K., Saitama, Japan.
Taku IzumiSophion Bioscience K.K., Saitama, Japan.
Mihoko Hagiwara-NagasawaDepartment of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.
Koki ChibaDepartment of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.
Ryota NishiyamaDrug Research Department, TOA EIYO LTD., Fukushima, Japan.
Satomi OyamaDrug Research Department, TOA EIYO LTD., Fukushima, Japan.
Yoshio NunoiDepartment of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.
Yoshinori TakeiDepartment of Translational Research and Cellular Therapeutics, Faculty of Medicine, Toho University, Tokyo, Japan.
Akio MatsumotoDepartment of Aging Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.
Atsushi SugiyamaDepartment of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.
Toho University · JPTOA EIYO (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oseltamivir has been shown to prolong the atrial conduction time and effective refractory period, and to suppress the onset of burst pacing-induced atrial fibrillation

Indexed as

dogsECGIK,AChoseltamivirpatch clamp assaypersistent atrial fibrillationpilsicainidesafety pharmacology

Identifiers

PMID33995006
PMCPMC8118603
OpenAlexW3157287319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.